Blog
RSS FeedPosted by Michael Wonder on 10 Aug 2020
Coming of age: emerging health preference research based on established scientific standards
10 August 2020 - Value in Health themed section enhances the scientific respectability and relevance of health preference research. ...
Posted by Michael Wonder on 10 Aug 2020
ICER to assess treatments for lupus nephritis
10 August 2020 - Report will be subject of New England CEPAC meeting in March 2021; Open Input now being accepted ...
Posted by Michael Wonder on 22 Jul 2020
COVID-19 and ISPOR conferences
22 July 2020 - ISPOR redesigns remaining conferences for 2020. ...
Posted by Michael Wonder on 21 Jul 2020
ICER publishes evidence report on obeticholic acid for the treatment of non-alcoholic steatohepatitis
21 July 2020 - Given the FDA’s recent decision to not grant accelerated approval for the treatment, ICER has canceled its ...
Posted by Michael Wonder on 20 Jul 2020
ICER posts draft scoping document for the assessment of anaemia in chronic kidney disease treatments
20 July 2020 - Document open to public comment until 7 August 2020 ...
Posted by Michael Wonder on 08 Jul 2020
ICER reschedules cystic fibrosis public meeting for 27 August 2020
8 July 2020 - Registration is now open. ...
Posted by Michael Wonder on 06 Jul 2020
ICER posts draft scoping document on high cholesterol
6 July 2020 - Document open to public comment until 24 July 2020. ...
Posted by Michael Wonder on 05 Jul 2020
Beyond the numbers: a critique of quantitative multi-criteria decision analysis
1 July 2020 - When setting priorities for health, there is broad agreement that a range of social values and ethical ...
Posted by Michael Wonder on 01 Jul 2020
ICER cancels public meeting for non-alcoholic steatohepatitis assessment
1 July 2020 - August 2020 public meeting cancelled; evidence report being posted on 21 July 2020. ...
Posted by Michael Wonder on 29 Jun 2020
ICER to assess treatments for anaemia in chronic kidney disease
26 June 2020 - Report will be subject of CTAF meeting in Feburary 2021; Open Input now being accepted until ...
Posted by Michael Wonder on 24 Jun 2020
ICER provides first update to pricing models for remdesivir as a treatment for COVID-19
24 June 2020 - Updated cost-recovery benchmark price now framed as a range with maximum of $1,600/10 day regimen when incorporating ...
Posted by Michael Wonder on 23 Jun 2020
The case for using novel value elements when assessing COVID-19 vaccines and therapeutics
23 June 2020 - In the span of mere weeks, the novel coronavirus (COVID-19) has upended modern life. Schools and businesses ...
Posted by Michael Wonder on 20 Jun 2020
ICER to assess whether the most significant prescription drug price increases are supported by new clinical evidence
19 June 2020 - Public input on drugs of concern will be accepted through 17 July 2020. ...
Posted by Michael Wonder on 16 Jun 2020
VA and ICER at three years: critics' concerns answered
15 June 2020 - As part of its national formulary management process, the Department of Veterans Affairs (VA) Pharmacy Benefits ...
Posted by Michael Wonder on 15 Jun 2020
COVID-19 and remdesivir: rethinking how we measure a drug’s ‘value’
15 June 2020 - As pharmaceutical and biotech companies scramble to identify treatments for COVID-19, a new disease that initially ...